Vancouver-based Veritas Pharma Inc. said its Cannevert Therapeutics Ltd. filed a provisional patent application to US Patent and Trademark Office for use of a specific cannabis strain in neuropathic pain.
“Neuropathic pain is a chronic pain associated with tissue and nerve fiber damage in conditions such as cancer and diabetes, and it is normally treated with anticonvulsants, antidepressants, anesthetics, and steroids,” said Veritas.
“In 2017, the Global Neuropathic Pain Market Research Report Forecast to 2023 is estimated to be $5.5 billion USD and it is expected to grow to $8.1 billion USD in 2023.
“The applicants have demonstrated effectiveness of a strain in a pain situation that is normally refractory to treatment with conventional analgesics.”
Veritas CEO Lui Franciosi said: “We want to compete in this large market and this patent application is an important research step as part of establishing a patent estate for Cannevert’s cannabis strains with therapeutic potential in pain.”